Taivex Therapeutics Corporation is a cancer drug development company established in Taipei in 2010. With a focus on addressing unmet medical needs and rising drug prices, Taivex is dedicated to developing oncology drugs that improve the health and quality of life for cancer patients. The company was co-founded by Taivex LLC (CA, USA) and China Petrochemical Development Corporation (CPDC).

Taivex has achieved significant milestones in its pursuit of breakthrough innovations. They have received approvals for Phase I studies and IND (Investigational New Drug) applications in both Taiwan and the United States for their products T-1101, T-1201, T-1301, and T-1501. Additionally, Taivex has collaborated with prestigious institutions such as the National Health Research Institutes (NHRI) and the Development Center for Biotechnology (DCB) to advance their drug development efforts.

With a commitment to sustainable development, Taivex aims to benefit not only individuals but also the community and the environment. For inquiries or further information, please contact Taivex Therapeutics Corporation through the provided contact details